FDA — authorised 22 June 2015
- Application: NDA204958
- Marketing authorisation holder: CHIESI
- Local brand name: KENGREAL
- Indication: POWDER — INTRAVENOUS
- Status: approved
🇺🇸 Kengreal in United States
FDA authorised Kengreal on 22 June 2015
Marketing authorisations
FDA — authorised 11 August 2025
- Application: ANDA213551
- Marketing authorisation holder: GLAND
- Local brand name: CANGRELOR
- Indication: POWDER — INTRAVENOUS
- Status: approved
Kengreal in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Metabolic approved in United States
Frequently asked questions
Is Kengreal approved in United States?
Yes. FDA authorised it on 22 June 2015; FDA authorised it on 11 August 2025.
Who is the marketing authorisation holder for Kengreal in United States?
CHIESI holds the US marketing authorisation.